← Back to Search

Behavioural Intervention

Transcranial Magnetic Stimulation for Substance Addiction

N/A
Waitlist Available
Led By Ryan Carnahan, PharmD, MS
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new magnetic pulse treatment for people struggling with methamphetamine addiction. The treatment targets specific brain areas to help reduce cravings and improve self-control. It aims to see if this method can be more effective than typical treatments.

Eligible Conditions
  • Stimulant Addiction
  • Methamphetamine Addiction
  • Substance Addiction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Retention in psychosocial treatment
Retention in the study
Secondary study objectives
Assessment of Recovery Capital
Brief Addiction Monitor Protective Factors Subscale
Brief Addiction Monitor Risk Factors Subscale
+18 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: MPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
Group II: DPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730

Find a Location

Who is running the clinical trial?

University of New MexicoOTHER
384 Previous Clinical Trials
3,525,937 Total Patients Enrolled
University of UtahOTHER
1,138 Previous Clinical Trials
1,791,647 Total Patients Enrolled
University of IowaLead Sponsor
465 Previous Clinical Trials
893,252 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top